-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Osteoporosis risk-assessment related lifestyle and metabolic factors: A population-based study
Lili You, Feng Li, Wanting Feng, Xiaoyi Wang, Meng Ren, Muchao Wu, Jin Zhang, Chuan Wang, Juying Tang, Xiaoyun Zhang, Li Yan, and Mingtong Xu
Research Article: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Uveitic macular edema: a stepladder treatment paradigm
Janine M Preble, Charles Stephen Foster
Clinical Trail Outcomes: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Quality-adjusted survival as an end point in breast cancer trials
AJ Martin, RJ Simes
Special Issue Article: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Novel treatment options for acute myelocytic leukemia
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ruxolitinib for myelofibrosis
Clodagh Keohane & Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Research involving pregnant women: trials and tribulations
Francoise Baylis, Scott A. Halperin
Clinical Trail Perspective: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Potential utility of biomarkers in the diagnosis and treatment of ALS
Benjamin Chee Chuan Cheah, Steve Vucic, Matthew Colm Kiernan
Review: Clinical Trail Outcomes: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Market authorization granted for Bydureon the first once-weekly medication for Type 2 diabetes
News and Views: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings
Kate Bushby, Edward Connor
Proceedings: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation
-
The process of drug development in pediatric oncology: a review of basic principals and a look into the future
Andre Tesainer Brunetto, Rafael Roesler, Ana Lucia Abujamra, Claudio Galvao de Castro, Gilberto chwartsmann, Algemir Lunardi Brunetto
Clinical Trail Outcomes: Clinical Investigation